<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01178918</url>
  </required_header>
  <id_info>
    <org_study_id>KOPA-H1N1-01</org_study_id>
    <nct_id>NCT01178918</nct_id>
  </id_info>
  <brief_title>Non-specific Response to H1N1 Vaccine</brief_title>
  <official_title>Enhanced Non-Specific T Lymphocytes Response to Influenza A (H1N1) AS03-Adjuvanted Vaccine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University Clinic of Pulmonary and Allergic Diseases Golnik</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University Clinic of Pulmonary and Allergic Diseases Golnik</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective observational study with recruitment of healthy volunteers from
      consecutive recipients of H1N1 influenza vaccine at the University Clinic of Respiratory and
      Allergic Diseases, Golnik, Slovenia.

      The purpose of this study is to evaluate certain safety aspects of adjuvanted influenza H1N1
      vaccines.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">July 1, 2012</completion_date>
  <primary_completion_date type="Actual">December 1, 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>T Cell Immune response monitoring after Influenza A (H1N1) AS03-Adjuvanted Vaccination</measure>
    <time_frame>At 3 weeks after vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>T Cell Immune response monitoring after Influenza A (H1N1) AS03-Adjuvanted Vaccination</measure>
    <time_frame>At 11 weeks after vaccination.</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">14</enrollment>
  <condition>Influenza H1N1</condition>
  <arm_group>
    <arm_group_label>Healthy volunteers from recipients of H1N1 vaccine</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy volunteers from consecutive recipients of H1N1 influenza vaccine at the University
        Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Recipients of H1N1 influenza vaccine.

          -  Healthy individuals with no signs of influenza or other infectious disease.

        Exclusion Criteria:

          -  Signs of influenza or other infectious disease in 1 month before study participation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Clinic of Respiratory and Allergic Diseases</name>
      <address>
        <city>Golnik</city>
        <zip>4204</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Slovenia</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>August 4, 2010</study_first_submitted>
  <study_first_submitted_qc>August 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2010</study_first_posted>
  <last_update_submitted>February 26, 2020</last_update_submitted>
  <last_update_submitted_qc>February 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University Clinic of Pulmonary and Allergic Diseases Golnik</investigator_affiliation>
    <investigator_full_name>Peter Koro≈°ec</investigator_full_name>
    <investigator_title>Head of Laboratory</investigator_title>
  </responsible_party>
  <keyword>Influenza H1N1</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Adjuvant</keyword>
  <keyword>T Lymphocytes</keyword>
  <keyword>Non-specific response</keyword>
  <keyword>Interleukin-2</keyword>
  <keyword>Non-specific T cell response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

